Press Release: VIRTTU : Virttu Biologics Announces Appointment Of Deirdre Y. Gillespie As Chief Executive Officer
LONDON, Oct. 19, 2015 /PRNewswire/ -- Virttu Biologics, a clinical stage biotechnology company pioneering the discovery and development of unique oncolytic immunotherapies for systemic and intra-tumoural delivery treatment of cancer, today announced that Deirdre Y. Gillespie, M.D....
Read full article »
CEO
Virttu is engaged in the discovery and development of oncolytic immunotherapy for the treatment of cancer.
Read more